Allergan Gets FDA Clearance For Xen Glaucoma Treatment

(RTTNews) - Allergan plc (AGN) Tuesday announced that the U.S. Food and Drug Administration has cleared the Xen Glaucoma Treatment System for use in the U.S.

The Xen system reduces intraocular pressure in patients and is indicated for the management of refractory glaucomas, where previous surgical treatment has failed or in patients with primary open angle glaucoma, and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy.

Allergan plans to launch the XEN Glaucoma Treatment System in the U.S. in early 2017.